Updated results and correlative FDG-PET analysis of a phase IB study of vemurafenib and cobimetinib (MEK inhibitor [GDC-0973]), in advanced BRAF(V600)- mutated melanoma (BRIM7)

Detalles Bibliográficos
Autores principales: Puzanov, Igor, McArthur, Grant, Gonzalez, Rene, Pavlick, Anna, Hamid, Omid, Gajewski, Thomas F, Yin, Ming, Fredrickson, Jill, Choong, Nicholas, Ribas, Antoni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Oral Presentation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4126212/
http://dx.doi.org/10.1186/1479-5876-12-S1-O7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4126212/
http://dx.doi.org/10.1186/1479-5876-12-S1-O7

Ejemplares similares